Table 1 Summary of evidence of interaction and effects of combination antifungal therapy against Candida spp investigated by in vitro, animal and clinical studies

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  **Authors, date** | **N** | **Combination/ comparator** | **Species** | **Major findings** |
| **In vitro** |
| *Flucytosine combinations* |
| **Flucytosine and Amphotericin B** |
| Dupont 19791 | 27 | Flucytosine + amphotericin B | *C. albicans* (26),*C. parapsilosis* (1) | Indifference (26 – *C. albicans*)Synergy (1 – *C. parapsilosis*) |
| Chen 19822 | 10 | Flucytosine + amphotericin B | *C. albicans* | Synergy (10) |
| Odds 19823 | 6 | Flucytosine + amphotericin B | *C. albicans* (3), *C. kefyr* (1), *C. tropicalis* (1), *C. krusei* (1) | Synergy (1)Indifference (5) |
| Scalarone 19924 | 10 | Flucytosine + amphotericin B | *C. albicans* (10) | Synergy (1)Indifference (9) |
| Lewis 20025 | 6 | Flucytosine + amphotericin B | *C. albicans* (3*),* *C. glabrata* (1), *C. krusei* (1*),* *C. tropicalis* (1) | Synergy (4 - 2 *C. albicans*, 1 *C. glabrata*, 1 *C. tropicalis*)Indifference (2 - 1 *C. albicans*, 1 *C. krusei*) |
| Te Dorsthorst 20026 | 27 | Flucytosine + amphotericin B | *C. albicans* (9), *C. glabrata* (9), *C. krusei* (9) | Synergy (1 *C. krusei*)Indifference (26 - 9 *C. albicans*, 9 *C. glabrata*, 8 *C. krusei*) |
| Alves 20127 | 68 | Flucytosine + amphotericin B | *C. glabrata* (34 FLZ-S, 34 FLZ-R) | FLZ-S:- Synergy (21)- Indifference (13)FLZ-R:- Synergy (26)- Indifference (8) |
| Bidaud 20198 | 15 | Flucytosine + amphotericin B | *C. auris* | Synergy (1)Indifference (14) |
| Chassot 20199 | 60 | Flucytosine + amphotericin B | *C. parapsilosis* (30 ECH-S, 10 ANF-R, 10 CSF-R, 10 MCF-R) | ECH-S:- Synergy (9)-Indifference (21)ANF-R:- Synergy (2)- Indifference (6)- Antagonism (2)CSF-R:- Indifference (7)- Antagonism (3)MCF-R:- Synergy (1)- Indifference (1)- Antagonism (8) |
| O’Brien 202010 | 13 | Flucytosine + amphotericin B | *C. auris* (4 AmB-R, 1 5FC-R) | Indifference (13) |
| O’Brien 2020a11 | 4 | Flucytosine + amphotericin B | *C. auris* (AmB-R, ECH-R, AZ-R) | Indifference (3)Antagonism (1) |
| Khalifa 202112 | 17 | Flucytosine + amphotericin B | *C. glabrata* | Indifference (17) |
| John 202313 | 11 | Flucytosine + amphotericin B | *C. auris* | Indifference (11)  |
| **Flucytosine and Echinocandins** |
| Karlowsky 200514 | 18 | Flucytosine + anidulafungin | *C. albicans (4),* *C. glabrata (4),* *C. krusei (2),* *C. tropicalis (4),* *C. parapsilosis (4)* | Indifference (18) |
| Alves 20127 | 68 | Flucytosine + caspofungin | *C. glabrata* (34 FLZ-S, 34 FLZ-R) | FLZ-S:- Synergy (10)- Indifference (23)- Antagonistic (1)FLZ-R:- Synergy (16)- Indifference (18) |
| Rosato 201215 | 13 | Flucytosine + anidulafungin | 13 *Candida* spp | Synergy (10)Indifference (3) |
| Bidaud 20198 | 15 | Flucytosine + micafungin | *C. auris* | Synergy (1)Indifference (14) |
| O’Brien 202010 | 42 | Flucytosine + anidulafungin/ micafungin/ caspofungin | *C. auris* (6 ECH-R, 2 5FC-R. | Synergy (4)Indifference (38) |
| O’Brien 2020a11 | 12 | Flucytosine + micafungin/ caspofungin/ anidulafungin | *C. auris* (AmB-R, ECH-R, AZ-R) | Indifference (8)Antagonism (4) |
| Khalifa 202112 | 17  | Flucytosine + caspofungin | *C. glabrata* (6 ECH-R) | Indifference |
| John 202313 | 11 | Flucytosine + anidulafungin | *C. auris* | Synergy (2)Indifference (9) |
| **Flucytosine and Azoles** |
| Dupont 19791 | 26 | Flucytosine + econazole/miconazole | *C. albicans* | Synergy (22)Indifference (4) |
| Odds 19823 | 12 | Flucytosine + ketoconazole/miconazole | *C. albicans (3),* *C. kefyr (1),* *C. tropicalis (1),* *C. krusei (1)*  | Synergy (1)Indifference (11) |
| Lewis 20025 | 6 | Flucytosine + fluconazole | *C. albicans* (3), *C. glabrata* (1), *C. krusei* (1), *C. tropicalis* (1) | Synergy (3 - 1 *C. albicans*, 1 *C. glabrata*, 1 *C. tropicalis*)Indifference (3 - 2 *C. albicans*, 1 *C. krusei*) |
| Te Dorsthorst 20026 | 27 | Flucytosine + fluconazole | *C. albicans* (9), *C. glabrata* (9), *C. krusei* (9) | Synergy (6 - 5 *C. albicans*, 1 *C. krusei*)Indifference (13 - 3 *C. albicans*, 2 *C. glabrata*, 8 *C. krusei*)Antagonism (8 - 1 *C. albicans*, 7 *C. glabrata*) |
| Barchiesi, 200416 | 20 | Flucytosine + voriconazole | *C. glabrata* | Synergy (1)Indifference (19) |
| Alves 20127 | 136 | Flucytosine + voriconazole/ itraconazole | *C. glabrata* (34 FLZ-S and 34 FLZ-R) | FLZ-S:- Synergy (16)- Indifference (38)- Antagonistic (14)FLZ-R:- Synergy (31)- Indifference (36)- Antagonistic (1) |
| Steier 201317 | 17 | Flucytosine + fluconazole/ posaconazole/ voriconazole/ itraconazole | *C. glabrata* (up to 8) | Antagonism (17) |
| Bidaud 20198 | 15 | Flucytosine + voriconazole | *C. auris* | Indifference (15) |
| Chassot 201918 | 120 | Flucytosine + fluconazole/ voriconazole | *C. parapsilosis* (30 ECH-S, 10 ANF-R, 10 CSF-R, 10 MCF-R) | ECH-S:- Synergy (9)- Indifference (47)- Antagonism (4)ANF-R:- Synergy (3)- Indifference (13)- Antagonism (4)CSF-R:- Indifference (15)- Synergy (5)MCF-R:- Synergy (2)- Indifference (2)- Antagonism (16) |
| O’Brien 202010 | 57 | Flucytosine + isavuconazole/ itraconazole/ posaconazole/ voriconazole | *C. auris* (14 FLZ-R, 2 5FC-R) | Synergy (1)Indifference (56) |
| O’Brien 2020a11 | 16 | Flucytosine + isavuconazole/ posaconazole/ voriconazole | *C. auris* (all AmB-R, ECH-R, AZ-R) | Indifference (13)Antagonism (3) |
| Khalifa 202112 | 68 | Flucytosine + fluconazole/ itraconazole/ voriconazole/ posaconazole | *C. glabrata* | Indifference (68) |
| John 202313 | 11 | Flucytosine + voriconazole | *C. auris* | Indifference (8)Antagonistic (3) |
| **Triple drug combinations – Flucytosine + Amphotericin B + Azoles** |
| Odds 19823 | 18 | Flucytosine + amphotericin B + ketoconazole/ miconazole | *C. albicans (3),* *C. kefyr (1),**C. tropicalis (1),* *C. krusei (1)* | Synergy (3)Indifference (9)+ KCZ + MCZ:- Synergy (3)- Indifference (3) |
| *Amphotericin combinations* |
| **Amphotericin B and Echinocandins** |
| Barchiesi 200519 | 2 | Amphotericin B + caspofungin | *C. glabrata* (2) | Indifference (2) |
| Barchiesi 200720 | 3 | Amphotericin B + caspofungin | *C. parapsilosis* (3) | Indifference (3) |
| Karlowsky 200514 | 18 | Amphotericin B + anidulafungin | *C. albicans (4),* *C. glabrata (4),* *C. krusei (2),**C. tropicalis (4),* *C. parapsilosis (4)* | Indifference (18) |
| Serena 200821 | 145 | Amphotericin B + micafungin | *C. krusei* (35), *C. albicans* (35), *C. parapsilosis* (15), *C. tropicalis* (15), *C. dubliniensis* (20), *C. glabrata* (15), *C. lusitaniae* (10) | Synergy (32)Indifference (113) |
| Tobudic 201022 | 22 | Amphotericin B + caspofungin | *C. albicans* (planktonic (11) & biofilms (11)) | Synergy (4 – all planktonic)Indifference (18) |
| Chaturvedi 201123 | 15 | Amphotericin B + anidulafungin/ caspofungin/ micafungin | *C. parapsilosis* (2), *C. albicans* (2),*C. glabrata* (1) | Synergy (5 - 1 *C. albicans*, 4 *C. parapsilosis*)Indifference (10) |
| Alves 20127 | 68 | Amphotericin B + caspofungin | *C. glabrata* (34 FLZ-S, 34 FLZ-R | FLZ-S:- Synergy (2)- Indifference (27)- Antagonism (5)FLZ-R:- Synergy (16)- Indifference (18) |
| Rosato 201215 | 13 | Amphotericin B + anidulafungin | 13 *Candida* spp | Synergy (9)Indifference (4) |
| Denardi 201724 | 60 | Amphotericin B + anidulafungin/caspofungin/ micafungin | *C. glabrata* (FLZ-R + CSF-R) | Synergy (14)Indifference (32)Antagonism (14) |
| Jaggavarapu 202025 | 10 | Amphotericin B + micafungin | *C. auris*  | Synergy (8)Indifference (2) |
| Reginatto 202026 | 9 | Amphotericin B + anidulafungin | *C. parapsilosis* x3,*C. albicans* x3,*C. tropicalis* x3 | Synergy to inhibit and remove biofilms (9) |
| Khalifa 202112 | 17 | Amphotericin B + caspofungin | *C. glabrata* (6 ECH-R) | Synergy (4) – all ECH-RIndifference (13) |
| Hernando-Ortiz 202427 | 15 | Amphotericin B + anidulafungin/ caspofungin/ micafungin | *C. auris* (4 non-aggregative, 1 aggregative) | Synergy (14)Indifference (1 – AMB + MFG against aggregative strain) |
| **Amphotericin B and Azoles** |
| Dupont 19791 | 26 | Amphotericin B + econazole/ miconazole | *C. albicans* (26) | Antagonism (26) |
| Odds 19823 | 18 | Amphotericin B + ketoconazole/ miconazole | *C. albicans* (3), *C. kefyr* (1), *C. tropicalis* (1), *C. krusei* (1) | Synergy (5)Indifference (7)+ KCZ + MCZ:- Synergy (1)- Indifference (5) |
| Petrou 199128 | 32\* | Amphotericin B + fluconazole/itraconazole/ketoconazole/miconazole | *C. albicans* (30), others (24) | Mean FICIs for species/drug combinations:Indifference (23)Antagonism (9) |
| Lewis 20025 | 6 | Amphotericin + fluconazole | *C. albicans* (3),*C. glabrata* (1), *C. krusei* (1), *C. tropicalis* (1) | Synergy (1 – *C. glabrata*)Indifference (5 – 3 *C. albicans*, 1 *C. krusei*, 1 *C. tropicalis*) |
| Barchiesi, 200416 | 20 | Amphotericin + voriconazole | *C. glabrata* | Synergy (2)Indifference (18) |
| Tobudic 201022 | 22 | Amphotericin B + posaconazole | *C. albicans* Planktonic (11)Biofilm (11) | Planktonic: indifference (11)Biofilm: synergy (11) |
| Chaturvedi 201123 | 10 | Amphotericin B + posaconazole/ voriconazole | *C. parapsilosis* (2), *C. albicans* (2),*C. glabrata* (1) | Synergy (2 – 1 *C. albicans*, 1 *C. glabrata)*Indifference (8) |
| Alves 20127 | 68 | Amphotericin + voriconazole | *C. glabrata* (34 FLZ-S, 34 FLZ-R) | FLZ-S:- Synergy (2)- Indifference (22) - Antagonism (10)FLZ-R:- Synergy (19)- Indifference (15) |
| Siopi 201529 | 24 | Amphotericin B + voriconazole | *C. glabrata* (2),*C. albicans* (2),*C. parapsilosis* (2), *C. krusei* (2),*C. tropicalis* (2), *C. kefyr* (2) | Indifference, occasional antagonism (FICI range 0.69-4.5) |
| Katragkou 201730 | 18 | Amphotericin B + isavuconazole | *C. glabrata* (4),*C. krusei* (3),*C. albicans* (4),*C. parapsilosis* (3), *C. tropicalis* (4) | Synergy (3 – *C. krusei*)Indifference (11 *– C. albicans, C. parapsilosis, C. tropicalis*)Antagonism (4 – *C. glabrata)* |
| Chassot 201918 | 120 | Amphotericin B + fluconazole/voriconazole | *C. parapsilosis* (30 ECH-S, 10 ANF-R, 10 CSF-R, 10 MCF-R) | ECH-S:- Indifference (29)- Antagonism (31)ANF-R:- Synergy (3)- Indifference (16)- Antagonism (1)CSF-R:- Indifference (11)- Antagonism (9)MCF-R:- Indifference (16)- Antagonism (4) |
| Khalifa 202112 | 68 | Amphotericin B + fluconazole/ itraconazole/ voriconazole/ posaconazole | *C. glabrata* (17) | Synergy (11)Indifference (57) |
| *Echinocandin combinations* |
| **Echinocandin and azoles** |
| Heyn 200531 | 98 | Micafungin + voriconazole | *C. albicans* (55), *C. dubliniensis* (19), *C. glabrata* (12), *C. parapsilosis* (12) | Synergy (3 - 1 *C. albicans*, 2 *C. glabrata*)Indifference (95) |
| Karlowsky 200614 | 36 | Anidulafungin + fluconazole/ itraconazole | *C. albicans* (4),*C. glabrata* (4), *C. krusei* (2),*C. tropicalis* (4),*C. parapsilosis* (4) | Synergy (1 *C. glabrata*)Indifference (35) |
| Chaturvedi 201123 | 30 | Anidulafungin/ caspofungin/ micafungin + posaconazole/ voriconazole | *C. parapsilosis* (2), *C. albicans* (2),*C. glabrata* (1) | Indifference (30) |
| Alves 20127 | 68 | Caspofungin + voriconaozle | *C. glabrata* (34 FLZ-S, 34 FLZ-R) | FLZ-S:- Indifference (29)- Antagonism (5)FLZ-R:- Synergy (10)- Indifference (24) |
| Rosato 201215 | 13 | Anidulafungin + fluconazole | 13 *Candida* spp | Synergy (10)Indifference (3) |
| Chen 201332 | 10 | Caspofungin + posaconazole | *C. albicans* | Synergy (10, including 4 ECH-R and 1 FLZ-R) |
| Siopi 201529 | 24 | Caspofungin + voriconazole | *C. glabrata (2),* *C. albicans (2),* *C. parapsilosis (2), C. krusei (2),* *C. tropicalis (2),* *C. kefyr (2)* | Indifference, occasional synergy (FICI range 0.5-2.06) |
| Denardi 201724 | 180 | Caspofungin/ micafungin/ anidulafungin + fluconazole/ posaconazole/ voriconazole | *C. glabrata* FLZ+CSF-R (20) | Synergy (76)Indifference (91)Antagonism (13) |
| Fakhim 201733 | 40 | Micafungin/ caspofungin and voriconazole/ fluconazole | *C. auris* (10 - all FLZ-R, 6 ECH-R) | Synergy (10)Indifference (30) |
| Katragkou 201730 | 18 | Micafungin + isavuconazole | *C. glabrata (*4),*C. krusei* (3),*C. albicans* (4), *C. parapsilosis* (3), *C. tropicalis* (4) | Synergy (10, *C. albicans, C.* *parapsilosis, C. krusei)*Indifference (8, *C. glabrata, C. tropicalis*) |
| Caballero 202134 | 18 | Anidulafungin/ caspofungin/ micafungin + isavuconazole | *C. auris* (6) | Synergy (18) |
| Khalifa 202112 | 68 | Caspofungin + fluconazole/ itraconazole/ voriconazole/ posaconazole | *C. glabrata* (17, 6 ECH-R) | Synergy (15)Indifference (53) |
| Nagy 202135 | 23 | Caspofungin + isavuconazole | *C. auris* (23 - South Asian (9); East Asian (4); South African (5); South American (5))  | Synergy (14)Indifference (9) |
| Pfaller 202136 | 72 | Anidulafungin + isavuconazole/ voriconazole | *C. auris* (36 - 32 FLZ-R, 9 VRC-NWT, 5 ECH-NWT) | Synergy (16)Indifference (55)Antagonism (1) |
| Balla 202237 | 8 | Caspofungin + posaconazole | *C. auris* (4 CSF-R) | Synergy (4)Indifference (4) |
| **Animal models** |
| *Flucytosine combinations* |
| **Flucytosine + amphotericin B** |
| Titsworth 197338 | Mice I/S (cortisone) 8/group | Flucytosine + amphotericin B | *C. albicans*  | Synergy (kidney culture sterility) for combination; reduced doses possible with combination |
| Rabinovich 197439  | Mice 44/group | Flucytosine + amphotericin B | *C. albicans* | Combination showed improved survival and reduced tissue burden |
| Polak 198240 | Mice | Flucytosine + amphotericin B  | *C. albicans* (3) | Synergy, or “definitely additive” for all strains including 5FC-R strain. Increased survival, dose-dependent synergy/indifference |
| Polak 198741 | Mice | Amphotericin B + flucytosine | *C. albicans* | Synergy, increased survival. Dose-dependent synergy/indifference |
| Thaler 198842 | Rabbits (12, neutropenic (Ara-C)) | Flucytosine + amphotericin B  | *C. albicans,* *C. tropicalis* (2) | Complete fungal eradication from kidney (most refractory site) |
| Atkinson 199543 | Mice (I/S with 5FU) | Flucytosine + amphotericin B  | *C. glabrata* (4- 2 FLZ-R) | Equal kidney/spleen burden reduction to AmB monotherapy; more effective than FLZ or 5FC monotherapy |
| Hope 200544 | Mice I/S (CP) 3/group | Flucytosine + Amphotericin B | *C. albicans*  | Constructed a model for in vivo interaction of amphotericin B and flucytosine in murine kidney ­- additive interaction |
| **Flucytosine + echinocandin**  |
| Mariné 200645 | Mice (I/S with CP/5FU, 10-20/group) | Flucytosine + micafungin | *C. glabrata* (1) | Reduced fungal burden compared to mono in spleen but not kidney |
| **Flucytosine + azoles** |
| Polak 198240 | Mice | Flucytosine + ketoconazole | *C. albicans* (3) | Indifference (3) |
| Polak 198741 | Mice | Flucytosine + itraconazole/ fluconazole | *C. albicans* | Synergy, increased survival. Dose-dependent synergy/indifference |
| Thaler 198842 | Rabbits (12, neutropenic (Ara-C)) | Flucytosine + ketoconazole | *C. albicans,* *C. tropicalis* (2) | Less effective at fungal eradication than KTZ monotherapy |
| Atkinson 199543 | Mice (I/S with 5FU) | Flucytosine + fluconazole | *C. glabrata* (4- 2 FLZ-R) | Additive effect for 1 isolate, no reduction in fungal burden for other 3 isolates |
| *Amphotericin combinations* |
| **Amphotericin B + echinocandin** |
| Hossain 200346 | 7 mice/ group | Amphotericin B + caspofungin | *C. albicans* (AZ-R) single clinical isolate | Combination has no significant increase in survival; significantly reduced kidney CFU vs monotherapy CSF and brain CFU vs monotherapy AmB |
| Barchiesi 200519 | 7-10 mice/group (neutropenic – CP) | Amphotericin B + caspofungin | *C. albicans* | Kidney tissue burden CSF+AmB < AmB or CSF |
| Olson 200547 | 7 mice/ group (I/S – CP) | Amphotericin B ± caspofungin/ micafungin (given sequentially and in combination) | *C. glabrata* | AmB+CSF/MCF significantly enhanced fungal clearance in kidneys / was sterilising in some cases |
| Mariné 200645 | Mice (I/S with CP/5FU, 10-20/group) | Amphotericin B + micafungin | *C. glabrata* (1) | More effective than monotherapy on survival and tissue fungal burden |
| Barchiesi 200720  | 8 mice/group (I/S - CP) | Amphotericin B + caspofungin | *C. parapsilosis* (3) | Kidney tissue burden CSF+AmB < AmB or CSF |
| **Amphotericin B + azole** |
| Polak 198240 | Mice | Amphotericin B + ketoconazole | *C. albicans* (3) | Synergy (1)Antagonism (2) |
| Polak 198741 | Mice | Amphotericin B + itraconazole | *C. albicans* | Mainly indifference and antagonism. Decreased survival |
| Thaler 198842 | Rabbits (12, neutropenic (Ara-C)) | Amphotericin B + ketoconazole | *C. albicans,* *C. tropicalis* (2) | Reduction in fungal burden in kidney, eradication in other organs (as does AmB monotherapy) |
| Atkinson 199543 | Mice (I/S with 5FU) | Amphotericin B + fluconazole | *C. glabrata* (4- 2 FLZ-R) | Ineffective, possible antagonism |
|  Sugar 199548 | Mice- I/S and non-I/S | Amphotericin B ± fluconazole | *C. albicans* | Survival and tissue burdencombination no better than AmB monotherapy |
| Sanati 199749 | Mice neutropenic (CP)Rabbit endocarditis | Amphotericin B ± fluconazole | *C. albicans* | Mice - survival similar in all arms- kidney tissue burden AmB±FLZ= AMB >FLZ- brain burden FLZ±AmB = FLZ >AmB Rabbit endocarditis – AMB >AmB±FLZ>FLZ |
| Sugar 199850 | Mice | Amphotericin B ± itraconazole | *C. albicans* | Combination has negative interaction on survival and kidney burden v AmB |
| Louie 199951 | Rabbit endocarditis, endophthalmitis and pyelonephritis (20-30/group) | Amphotericin B + fluconazole | *C. albicans* | Eye (vitreous) fungal burden: faster clearance but equivalent d14 efficacy to monotherapiesKidney/heart valve fungal burden: more active than FLZ monotherapy at reducing but less effective than AmB monotherapy.Similar d14/21 efficacy to monotherapies. |
| Louie 199952 | Mice | Amphotericin B ± fluconazole | *C. albicans* FLZ-S (1) and FLZ-R (3) | AmB>AmB+FLZ>FLZ for survivalTissue burden kidney AmB=AmB+FLZConcludes that AmB+FLZ antagonistic (FLZ-S), or additive (FLZ-R) |
| Louie 200153 | Rabbit endocarditis and pyelonephritis | Amphotericin B ± fluconazole | *C. albicans* | Pre-exposure of *C. albicans* to FLZ reduces fungal susceptibility to AmB.AmB+FLZ most rapidly sterilised kidneys and cardiac vegetations |
| Meletiadis 202354 | Neutropenic mice | Amphotericin B + posaconazole (3 different doses) | *C. albicans* | Kidney burden - synergistic (low AmB dose) and antagonistic (intermediate/high AmB doses)  |
| **Echinocandin + azole** |
| Graybill 200355 | 8-12 mice/ group | Caspofungin + fluconazole | *C. albicans* | CSF>CSF±FLZ>FLZ in reducing kidney CFU |
| Mariné 200645 | Mice (I/S with CP/5FU, 10-20/group) | Micafungin + fluconazole | *C. glabrata* (1) | Less effective than monotherapy on tissue fungal burden |
| Chen 201332 | 5 mice/ group | Caspofungin + posaconazole | *C. albicans,* FLZ-R and ECH-R FKS mutant strain | Combination showed improved survival in wild type and FLZ-R isolate |
| Nagy 202135 | 8 mice/ group (I/S – CP) | Caspofungin + isavuconazole | *C. auris* | Combination showed (non-significant) reduction in kidney tissue burden compared to CSF monotherapy  |
| **Clinical studies** |
| **Flucytosine + amphotericin B** |
| Kujath 199356 | Randomised trial,n = 40Deep-seated candidiasis in surgical patients | Fluconazole (400mg STAT, 300mg/d) (20) vs amphotericin B (0.5 mg/kg) + flucytosine (3 x 2.5 g) (20) | *C. albicans* (34), *C. glabrata*(7), *C. troplicalis*(3)Some mixed infection | Earlier elimination with AmB/5FC: 5.5d vs 8.5dSimilar elimination/reduction rates: 17/20 (85%) with AmB/5FC vs 18/20 (90%) with FLZ)Similar mortality: 5/20 (25%) with AmB/5FC, 6/20 (30%) with FLZNephrotoxicity leading to 1 treatment failure with AmB/5FC. No other toxicity |
| Abele-Horn 199657 | Randomisedtrial72 Systemiccandidiasis inICU | Fluconazole (400mg STAT,200mg/d) (36) vsamphotericin B (1-1.5 mg/kg)+ flucytosine (3 x 2.5 g) (36) | *C. albicans,* *C. glabrata,* *C. tropicalis,* *C. krusei,* *C. guillermondii**21 x mixed**infection* | Successful pathogen eradication at end of treatment in 42/52 (83%) with AmB/5FC vs 22/46 (48%) with FLZ p<0.001.Similar overall cure (61% vs 56%)and mortality (39% vs 36%)Nephrotoxicity: 31% in AmB/5FC vs0% in FLZ |
| **Fluconazole + amphotericin B** |
| Rex 200358 | Randomised trial, n = 219 Candida bloodstream infection (candidaemia) | Fluconazole(800mg) ± amphotericin B | Non-*krusei Candida* spp | Combination had higher success rates (69% vs 56%, p=0.043):- Improved blood stream clearance: 94% vs 83% (p=0.02)- 38% lower odds of failure with combined therapy- No antagonismNo difference in 90d mortality (39, 40%), higher nephrotoxicity in combined treatment |

Abbreviations: AmB = Amphotericin B; ECH = Echinocandin; CSF = Caspofungin; MCF = Micafungin; ANF = Anidulafungin; 5FC = Flucytosine; AZ = Azole; FLZ = Fluconazole; MCZ = Miconazole; PSZ = Posaconazole; VRC = Voriconazole; NWT = Non-Wild Type; -S, -R = sensitive, resistant; I/S = Immunosuppression.

Studies included if investigating antifungal drugs currently in use, *in vitro* studies included if used checkerboard techniques that reported fractional inhibitor concentration indices (FICI), defining synergy as FICI ≤0.5, indifferent 0.5-4.0, and antagonistic >4.

\*Mean FICIs for each *Candida* species/antifungal combination.

**References**

1. Dupont, B. & Drouhet, E. *In vitro* synergy and antagonism of antifungal agents against yeast-like fungi. *Postgrad. Med. J.* **55**, 683–686 (1979).

2. Chen, H. H., Liushih, R. N. & Hsieh, W. C. Combined in vitro activity of amphotericin B and 5-fluorocytosine against Cryptococcus neoformans and Candida albicans. *Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi* **15**, 106–112 (1982).

3. Odds, F. C. Interactions among amphotericin B, 5-fluorocytosine, ketoconazole, and miconazole against pathogenic fungi in vitro. *Antimicrob. Agents Chemother.* **22**, 763–770 (1982).

4. Scalarone, G. M., Mikami, Y., Kurita, N., Yazawa, K. & Miyaji, M. Comparative studies on the postantifungal effect produced by the synergistic interaction of flucytosine and amphotericin B on Candida albicans. *Mycopathologia* **120**, 133–138 (1992).

5. Lewis, R. E. Comparison of Etest, chequerboard dilution and time-kill studies for the detection of synergy or antagonism between antifungal agents tested against Candida species. *J. Antimicrob. Chemother.* **49**, 345–351 (2002).

6. Te Dorsthorst, D. T. A. *et al.* In vitro interaction of flucytosine combined with amphotericin B or fluconazole against thirty-five yeast isolates determined by both the fractional inhibitory concentration index and the response surface approach. *Antimicrob. Agents Chemother.* **46**, 2982–2989 (2002).

7. Alves, I. A. *et al.* Effects of antifungal agents alone and in combination against Candida glabrata strains susceptible or resistant to fluconazole. *Mycopathologia* **174**, 215–221 (2012).

8. Bidaud, A. L., Botterel, F., Chowdhary, A. & Dannaoui, E. In vitro antifungal combination of flucytosine with amphotericin B, voriconazole, or micafungin against Candida auris shows no antagonism. *Antimicrob. Agents Chemother.* **63**, e01393-19, AAC.01393-19 (2019).

9. Chassot, F. *et al.* Exploring the In Vitro Resistance of Candida parapsilosis to Echinocandins. *Mycopathologia* **181**, 663–670 (2016).

10. O’Brien, B., Chaturvedi, S. & Chaturvedi, V. In Vitro Evaluation of Antifungal Drug Combinations against Multidrug-Resistant Candida auris Isolates from New York Outbreak. *Antimicrob. Agents Chemother.* **64**, e02195-19 (2020).

11. O’Brien, B., Liang, J., Chaturvedi, S., Jacobs, J. L. & Chaturvedi, V. Pan-resistant Candida auris: New York subcluster susceptible to antifungal combinations. *Lancet Microbe* **1**, e193–e194 (2020).

12. Khalifa, H. O., Majima, H., Watanabe, A. & Kamei, K. In Vitro Characterization of Twenty-One Antifungal Combinations against Echinocandin-Resistant and -Susceptible Candida glabrata. *J. Fungi Basel Switz.* **7**, 108 (2021).

13. John, L. L. H. *et al.* Heightened Efficacy of Anidulafungin When Used in Combination with Manogepix or 5-Flucytosine against Candida auris In Vitro. *Antimicrob. Agents Chemother.* **67**, e01645-22 (2023).

14. Karlowsky, J. A., Hoban, D. J., Zhanel, G. G. & Goldstein, B. P. In vitro interactions of anidulafungin with azole antifungals, amphotericin B and 5-fluorocytosine against Candida species. *Int. J. Antimicrob. Agents* **27**, 174–177 (2006).

15. Rosato, A. *et al.* In vitro synergy testing of anidulafungin with fluconazole, tioconazole, 5-flucytosine and amphotericin B against some Candida spp. *Med. Chem. Shariqah United Arab Emir.* **8**, 690–698 (2012).

16. Barchiesi, F. *et al.* In Vitro Activities of Voriconazole in Combination with Three Other Antifungal Agents against Candida glabrata. *Antimicrob. Agents Chemother.* **48**, 3317–3322 (2004).

17. Steier, Z. *et al.* Flucytosine Antagonism of Azole Activity versus Candida glabrata: Role of Transcription Factor Pdr1 and Multidrug Transporter Cdr1. *Antimicrob. Agents Chemother.* **57**, 5543–5547 (2013).

18. Chassot, F. *et al.* Activity of antifungal agents alone and in combination against echinocandin-susceptible and -resistant Candida parapsilosis strains. *Rev. Iberoam. Micol.* **36**, 44–47 (2019).

19. Barchiesi, F. *et al.* Caspofungin in combination with amphotericin B against Candida glabrata. *Antimicrob. Agents Chemother.* **49**, 2546–2549 (2005).

20. Barchiesi, F., Spreghini, E., Tomassetti, S., Giannini, D. & Scalise, G. Caspofungin in Combination with Amphotericin B against Candida parapsilosis. *Antimicrob. Agents Chemother.* **51**, 941–945 (2007).

21. Serena, C. *et al.* In Vitro Interactions of Micafungin with Amphotericin B against Clinical Isolates of Candida spp. *Antimicrob. Agents Chemother.* **52**, 1529–1532 (2008).

22. Tobudic, S., Kratzer, C., Lassnigg, A., Graninger, W. & Presterl, E. In vitro activity of antifungal combinations against Candida albicans biofilms. *J. Antimicrob. Chemother.* **65**, 271–274 (2010).

23. Chaturvedi, V. *et al.* Multilaboratory Testing of Two-Drug Combinations of Antifungals against Candida albicans, Candida glabrata, and Candida parapsilosis. *Antimicrob. Agents Chemother.* **55**, 1543–1548 (2011).

24. Denardi, L. B. *et al.* Activity of Combined Antifungal Agents Against Multidrug-Resistant Candida glabrata Strains. *Mycopathologia* **182**, 819–828 (2017).

25. Jaggavarapu, S., Burd, E. M. & Weiss, D. S. Micafungin and amphotericin B synergy against Candida auris. *Lancet Microbe* **1**, e314–e315 (2020).

26. Reginatto, P. *et al.* Rational selection of antifungal drugs to propose a new formulation strategy to control Candida biofilm formation on venous catheters. *Braz. J. Microbiol. Publ. Braz. Soc. Microbiol.* **51**, 1037–1049 (2020).

27. Hernando-Ortiz, A. *et al.* Efficacy of the combination of amphotericin B and echinocandins against Candida auris in vitro and in the Caenorhabditis elegans host model. *Microbiol. Spectr.* **12**, e0208623 (2024).

28. Petrou, M. A. & Rogers, T. R. Interactions in vitro between polyenes and imidazoles against yeasts. *J. Antimicrob. Chemother.* **27**, 491–506 (1991).

29. Siopi, M., Siafakas, N., Zerva, L. & Meletiadis, J. Evaluation of paper gradient concentration strips for antifungal combination testing of Candida spp. *Mycoses* **58**, 679–687 (2015).

30. Katragkou, A. *et al.* In vitro combination therapy with isavuconazole against Candida spp. *Med. Mycol.* **55**, 859–868 (2017).

31. Heyn, K., Tredup, A., Salvenmoser, S. & Müller, F.-M. C. Effect of voriconazole combined with micafungin against Candida, Aspergillus, and Scedosporium spp. and Fusarium solani. *Antimicrob. Agents Chemother.* **49**, 5157–5159 (2005).

32. Chen, Y.-L., Lehman, V. N., Averette, A. F., Perfect, J. R. & Heitman, J. Posaconazole Exhibits In Vitro and In Vivo Synergistic Antifungal Activity with Caspofungin or FK506 against Candida albicans. *PLoS ONE* **8**, e57672 (2013).

33. Fakhim, H. *et al.* In Vitro Interactions of Echinocandins with Triazoles against Multidrug-Resistant Candida auris. *Antimicrob. Agents Chemother.* **61**, e01056-17 (2017).

34. Caballero, U. *et al.* In Vitro Synergistic Interactions of Isavuconazole and Echinocandins against Candida auris. *Antibiotics* **10**, 355 (2021).

35. Nagy, F. *et al.* In vitro and in vivo interaction of caspofungin with isavuconazole against Candida auris planktonic cells and biofilms. 2021.03.08.434267 Preprint at https://doi.org/10.1101/2021.03.08.434267 (2021).

36. Pfaller, M. A. *et al.* Evaluation of Synergistic Activity of Isavuconazole or Voriconazole plus Anidulafungin and the Occurrence and Genetic Characterization of Candida auris Detected in a Surveillance Program. *Antimicrob. Agents Chemother.* **65**, e02031-20 (2021).

37. Balla, N. *et al.* Synergistic Interaction of Caspofungin Combined with Posaconazole against FKS Wild-Type and Mutant Candida auris Planktonic Cells and Biofilms. *Antibiot. Basel Switz.* **11**, 1601 (2022).

38. Titsworth, E. & Grunberg, E. Chemotherapeutic activity of 5-fluorocytosine and amphotericin B against Candida albicans in mice. *Antimicrob. Agents Chemother.* **4**, 306–308 (1973).

39. Rabinovich, S., Shaw, B. D., Bryant, T. & Donta, S. T. Effect of 5-fluorocytosine and amphotericin B on Candida albicans infection in mice. *J. Infect. Dis.* **130**, 28–31 (1974).

40. Polak, A., Scholer, H. J. & Wall, M. Combination Therapy of Experimental Candidiasis, Cryptococcosis and Aspergillosis in Mice. *Chemotherapy* **28**, 461–479 (1982).

41. Polak, A. Combination therapy of experimental candidiasis, cryptococcosis, aspergillosis and wangiellosis in mice. *Chemotherapy* **33**, 381–395 (1987).

42. Thaler, M., Bacher, J., O’Leary, T. & Pizzo, P. A. Evaluation of Single-Drug and Combination Antifungal Therapy in an Experimental Model of Candidiasis in Rabbits with Prolonged Neutropenia. *J. Infect. Dis.* **158**, 80–88 (1988).

43. Atkinson, B. A. *et al.* Comparison of fluconazole, amphotericin B and flucytosine in treatment of a murine model of disseminated infection with *Candida glabrata* in immunocompromised mice. *J. Antimicrob. Chemother.* **35**, 631–640 (1995).

44. Hope, W. W. *et al.* Surface Response Modeling to Examine the Combination of Amphotericin B Deoxycholate and 5‐Fluorocytosine for Treatment of Invasive Candidiasis. *J. Infect. Dis.* **192**, 673–680 (2005).

45. Marine, M., Serena, C., Pastor, F. J. & Guarro, J. Combined antifungal therapy in a murine infection by Candida glabrata. *J. Antimicrob. Chemother.* **58**, 1295–1298 (2006).

46. Hossain, M. A., Reyes, G. H., Long, L. A., Mukherjee, P. K. & Ghannoum, M. A. Efficacy of caspofungin combined with amphotericin B against azole-resistant Candida albicans. *J. Antimicrob. Chemother.* **51**, 1427–1429 (2003).

47. Olson, J. A., Adler-Moore, J. P., Smith, P. J. & Proffitt, R. T. Treatment of Candida glabrata Infection in Immunosuppressed Mice by Using a Combination of Liposomal Amphotericin B with Caspofungin or Micafungin. *Antimicrob. Agents Chemother.* **49**, 4895–4902 (2005).

48. Sugar, A. M., Hitchcock, C. A., Troke, P. F. & Picard, M. Combination therapy of murine invasive candidiasis with fluconazole and amphotericin B. *Antimicrob. Agents Chemother.* **39**, 598–601 (1995).

49. Sanati, H., Ramos, C. F., Bayer, A. S. & Ghannoum, M. A. Combination therapy with amphotericin B and fluconazole against invasive candidiasis in neutropenic-mouse and infective-endocarditis rabbit models. *Antimicrob. Agents Chemother.* **41**, 1345–1348 (1997).

50. Sugar, A. M. & Liu, X.-P. Interactions of Itraconazole with Amphotericin B in the Treatment of Murine Invasive Candidiasis. *J. Infect. Dis.* **177**, 1660–1663 (1998).

51. Louie, A. *et al.* Efficacies of high-dose fluconazole plus amphotericin B and high-dose fluconazole plus 5-fluorocytosine versus amphotericin B, fluconazole, and 5-fluorocytosine monotherapies in treatment of experimental endocarditis, endophthalmitis, and pyelonephritis due to Candida albicans. *Antimicrob. Agents Chemother.* **43**, 2831–2840 (1999).

52. Louie, A., Banerjee, P., Drusano, G. L., Shayegani, M. & Miller, M. H. Interaction between Fluconazole and Amphotericin B in Mice with Systemic Infection Due to Fluconazole-Susceptible or -Resistant Strains of Candida albicans. *Antimicrob. Agents Chemother.* **43**, 2841–2847 (1999).

53. Louie, A. *et al.* Impact of the Order of Initiation of Fluconazole and Amphotericin B in Sequential or Combination Therapy on Killing of Candida albicans In Vitro and in a Rabbit Model of Endocarditis and Pyelonephritis. *Antimicrob. Agents Chemother.* **45**, 485–494 (2001).

54. Meletiadis, J., Beredaki, M.-I., Elefanti, A., Pournaras, S. & Muller, A. In Vitro–In Vivo Correlation of Posaconazole–Amphotericin B Combination against Candida albicans: In Vitro Interacting Concentrations Are Associated with In Vivo Free Drug Levels. *J. Fungi* **9**, 434 (2023).

55. Graybill, J. R., Bocanegra, R., Najvar, L. K., Hernandez, S. & Larsen, R. A. Addition of Caspofungin to Fluconazole Does Not Improve Outcome in Murine Candidiasis. *Antimicrob. Agents Chemother.* **47**, 2373–2375 (2003).

56. Kujath, P., Boos, C., Lerch, K. & Kochendörfer, P. Comparative study of the efficacy of fluconazole versus amphotericin B/flucytosine in surgical patients with systemic mycoses. *Infection* **21**, 376–382 (1993).

57. Abele-Horn, M. *et al.* A randomized study comparing fluconazole with amphotericin B/5-flucytosine for the treatment of systemicCandida infections in intensive care patients. *Infection* **24**, 426–432 (1996).

58. Rex, J. H. *et al.* A Randomized and Blinded Multicenter Trial of High‐Dose Fluconazole plus Placebo versus Fluconazole plus Amphotericin B as Therapy for Candidemia and Its Consequences in Nonneutropenic Subjects. *Clin. Infect. Dis.* **36**, 1221–1228 (2003).